Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma
2024
Correction on Immunotherapy Case Report
Sample size: 1
publication
Author Information
Author(s): Wang Tongshan, Chen Muyang, Wang Anpeng, Zhang Hao
Primary Institution: Nanjing Medical University
Conclusion
The correction clarifies that the patient was treated with camrelizumab instead of pembrolizumab, achieving significant therapeutic success.
Supporting Evidence
- The patient was initially treated with camrelizumab, achieving partial tumor remission.
- The patient continued treatment for a total of 27 cycles of camrelizumab.
- The patient transitioned to a combination therapy and then back to camrelizumab due to side effects.
Takeaway
This study talks about a patient with a rare lung cancer who did well on a specific treatment, and they fixed a mistake in the report about the medicine used.
Participant Demographics
68-year-old male patient
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website